Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a.
18 January 2023 ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas
. | January 18, 2023
16.12.2022 - Eurostars-3 collaborative project with Danish institutions ImProTher and University of Copenhagen Global budget of 1.4 million euros; Oryzon to receive up to 400,000 euros Project will assess the efficacy of iadademstat in combination with . Seite 1